Leptin    (DrugBank: Leptin)

2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病1
265脂肪萎縮症15

6. パーキンソン病 [臨床試験数:2,123,薬物数:2,046(DrugBank:324),標的遺伝子数:183,標的パスウェイ数:198
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,123 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000017036
2015/04/0303/04/2015Association of ghrelin and leptin in cardiovascular autonomic dysfunction in patients with primary dysautonomia. autonomic failure such as Parkinson's diseaseblood test of Leptin and Ghrelin
blood test of Leptin and Ghrelin
Nagoya University Graduate School of MedicineNULLComplete: follow-up complete40years-oldNot applicableMale and Female50Not applicableJapan

265. 脂肪萎縮症 [臨床試験数:109,薬物数:164(DrugBank:59),標的遺伝子数:26,標的パスウェイ数:94
Searched query = "Lipodystrophy", "Berardinelli-Seip syndrome", "Lawrence syndrome", "Barraquer-Simons syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
15 / 109 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04159415
(ClinicalTrials.gov)
January 7, 20207/11/2019Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized LipodystrophyA Randomized, Double-Blind, Placebo-Controlled Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized LipodystrophyGeneralized LipodystrophyDrug: Placebo;Drug: Low-Dose REGN4461;Drug: High-dose REGN4461Regeneron PharmaceuticalsNULLActive, not recruiting12 YearsN/AAll26Phase 2United States
2EUCTR2017-003014-22-AT
(EUCTR)
25/06/201829/05/2018Leptin in hepatic lipid metabolism in humansThe role of leptin in regulating hepatic lipid metabolism in humans - Leptin and hepatic lipid metabolism lipodystrophy patients, patients after liver transplantation and healthy controls;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]Trade Name: Myalept
Product Name: Myalept
INN or Proposed INN: metrelpetin
Other descriptive name: METRELEPTIN
Medical University of ViennaNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
43Phase 2Austria
3NCT03262610
(ClinicalTrials.gov)
February 17, 201722/8/2017Setemelanotide in a Single Patient With Partial LipodystrophyExpanded-access for the Use of Setemelanotide in a Single Patient With Partial Lipodystrophy (LD) Associated With Leptin Deficiency and Multiple Autoimmune DiseasesHypertriglyceridemiaDrug: SetmelanotideRhythm Pharmaceuticals, Inc.NULLNo longer available15 Years15 YearsFemaleUnited States
4NCT02654977
(ClinicalTrials.gov)
September 29, 201520/1/2015CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial LipodystrophyCLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Recombinant Human Leptin (METRELEPTIN) in Various Forms of Partial LipodystrophyFamilial Partial Lipodystrophy;Nonalcoholic Steatohepatitis;NAFLDDrug: MetreleptinUniversity of MichiganNULLCompleted5 YearsN/AAll11Phase 2United States
5NCT01778556
(ClinicalTrials.gov)
January 26, 201326/1/2013Short-term Effects of Leptin in People With LipodystrophyShort Term Effects of Leptin Withdrawal or Initiation in Lipodystrophy Independent of Energy IntakeLipodystrophyBiological: MetreleptinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NULLCompleted14 Years70 YearsAll25Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01679197
(ClinicalTrials.gov)
October 8, 201231/8/2012Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With LipodystrophyClinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With LipodystrophyFatty Liver Disease, Nonalcoholic;Nonalcoholic Steatohepatitis;LipodystrophyDrug: MetreleptinUniversity of MichiganNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed5 YearsN/AAll23Phase 2United States
7JPRN-UMIN000002818
2010/08/0101/01/2010Phase 2 trial of leptin-replacement therapy for patients with lipodystrophy lipodystrophyadministration of recombinant methionyl human leptinDepartment of Medicine and Clinical Science, Kyoto University Graduate School of MedicineTranslational Research Center, Kyoto University HospitalNULLComplete: follow-up complete6years-oldNot applicableMale and Female3Phase 2Japan
8JPRN-UMIN000003679
2010/08/0101/06/2010Long-term safety clinical trial of leptin-replacement therapy in patients with lipodystrophy after introduction of the treatment lipodytrophysubcutaneous injection of human recombinant leptinKyoto University HospitalNULLComplete: follow-up complete6years-oldNot applicableMale and Female11Not selectedJapan
9NCT00362440
(ClinicalTrials.gov)
August 20069/8/2006Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic SyndromeA Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome: A Randomized, Double-blind, Placebo-controlled Clinical TrialHIV LipodystrophyDrug: Leptin;Drug: Pioglitazone or metformin;Drug: PlaceboBeth Israel Deaconess Medical CenterAmerican Diabetes AssociationCompleted18 YearsN/AAll9Phase 2United States
10NCT00896298
(ClinicalTrials.gov)
April 20068/5/2009Trial of Leptin Replacement Therapy in Patients With LipodystrophyDouble-Blind, Placebo-Controlled Trial of Leptin Replacement Therapy in Patients With LipodystrophyHypoleptinemia;Generalized Lipodystrophy;Partial Lipodystrophy;Insulin ResistanceDrug: Leptin;Drug: PlaceboUniversity of Texas Southwestern Medical CenterNULLCompleted6 Years70 YearsAll25Phase 2;Phase 3United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT01511016
(ClinicalTrials.gov)
February 200311/1/2012Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy SyndromeThe Effect of Leptin Therapy on Abnormal Lipid Kinetics in Subjects With HIV Lipodystrophy SyndromeHIV LipodystrophyDrug: Human recombinant leptin (metreleptin);Drug: PlaceboBaylor College of MedicineNULLCompleted18 Years64 YearsMale17N/AUnited States
12NCT00461552
(ClinicalTrials.gov)
January 200316/4/2007Therapeutic Approaches to HAART-Induced LipodystrophyTherapeutic Approaches to HAART-Induced LipodystrophyHIV Infections;LipodystrophyDrug: Leptin;Other: PlaceboUniversity of Texas Southwestern Medical CenterAmylin Pharmaceuticals, LLC.Completed14 Years65 YearsAll23Phase 2United States
13NCT00140244
(ClinicalTrials.gov)
December 200130/8/2005Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic SyndromeRole of Leptin in Highly Active Antiretroviral Therapy (HAART)-Induced Lipodystrophy and Metabolic Syndrome in HAART-Treated HIV PatientsHAART-induced Lipodystrophy and Metabolic SyndromeDrug: r-metHuLeptin;Drug: PlaceboBeth Israel Deaconess Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);AmgenCompleted18 YearsN/AAll7Phase 2United States
14NCT00025883
(ClinicalTrials.gov)
October 200127/10/2001Leptin to Treat LipodystrophyLong-Term Efficacy of Leptin Replacement in Treatment of LipodystrophyLipodystrophyDrug: MetreleptinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NULLCompleted6 MonthsN/AAll103Phase 2United States
15NCT00005905
(ClinicalTrials.gov)
June 20009/6/2000Leptin to Treat LipodystrophyEfficacy of Leptin Replacement in Treatment of LipodystrophyLipodystrophyDrug: hu Leptin (A-100)National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NULLCompletedN/AN/ABoth20Phase 2United States